Research Article

Huoxue Qianyang Qutan Recipe Protects against Early Renal Damage Induced by Obesity-Related Hypertension via the SIRT1/NF-κB/IL-6 Pathway: Integrating Network Pharmacology and Experimental Validation-Based Strategy

Mingzhu Wang,1 Jianhua Li,1 Mingtai Gui,1 Bo Lu,1 Lei Yao,1 Xunjie Zhou,1 Moyi Shi,1 Liang Hu,2 and Deyu Fu1

1 Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
2 Academy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Correspondence should be addressed to Deyu Fu; fdy65@126.com

Received 26 February 2022; Accepted 13 May 2022; Published 27 May 2022

Academic Editor: Youhua Wang

Copyright © 2022 Mingzhu Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Obesity is recognized as not only a major contributing factor to cardiovascular diseases but also an independent risk factor for end-stage renal disease. Previous studies have found that Huoxue Qianyang Qutan Recipe (HQQR) could reduce urinary microalbumin in patients with obesity-related hypertension (OBH). However, the renal protective activity of HQQR in OBH and its molecular targets involved remains ambiguous. In this work, we investigate the mechanism of HQQR against OBH-induced early renal damage using integrating network pharmacology and experimental validation-based strategy. First, via network pharmacology, IL-6 is identified as one of the key targets of HQQR against early renal damage in hypertension, and inhibition of inflammation is a crucial process. Second, in in vivo experiments, HQQR can lower blood pressure, lose weight, and restore metabolic abnormalities in OBH rats, which could be associated with the effects on protecting early renal damage. Finally, in the mechanism, HQQR increases SIRT1 mRNA and protein expression consistent with reduction of NF-κB acetylation and suppressed the p65-mediated inflammatory signaling pathway. As a result, HQQR robustly inhibits OBH-induced renal inflammation by reducing IL-6 mRNA and protein levels in the renal tissue and the release of IL-6 in serum of OBH rats. This study aims to provide a multimethod (network pharmacology-animal experiment) and multilevel (component-target-pathway) strategy for the prevention and treatment of OBH-induced target organ damage by traditional Chinese medicine.

1. Introduction

Hypertension is the leading risk factor for death worldwide [1]. Excess weight gain, as a major cause of hypertension, accounts for 65–75% of the hypertensive risk [2]. With prolonged obesity, obesity-related hypertension (OBH) contributes directly to cardiovascular disease (CVD) and target organ damage (TOD), especially renal injury [3]. OBH becomes more difficult to control due to dyslipidemia, insulin resistance, and inflammation, often requiring multiple antihypertensive drugs and treatment of other risk factors [4].

Major TOD of OBH includes higher prevalence of hypertension-associated cardiorenal and metabolic disorders. Nevertheless, the mechanisms of renal injury induced by TOD have not been fully elucidated. Accumulating evidences unravel that inflammation and the immune system which interact synergistically with OBH may cause renal injury [5, 6]. Meanwhile, many investigations have also focused on the close molecular coordination between the inflammation and energy metabolic supply in OBH [7, 8], suggesting that chronic inflammation with metabolic abnormalities accounts for a far higher proportion of renal damage and CVD [9]. Therefore,
new multifunctional agents to reduce the risk of end-stage renal diseases induced by OBH face a major challenge owing to the pathogenic mechanisms attributed to multiroute and multi-target pathways.

Traditional Chinese medicine (TCM) as a complementary medicine is becoming increasingly available worldwide. Chinese herbs, as a representative of multi-target interventions, have been proved useful in relieving hypertension-related symptoms [10, 11]. It has recently been shown that Huoxue Qianyang Qutan Recipe (HQQR) could be effective in left ventricular hypertrophy and cardiac remodeling in OBH rats. The mechanism may be relevant to improving mitochondrial function through the SIRT1/PGC-1α deacetylation pathway and ATF6-CHOP endoplasmic reticulum stress signaling pathway [12, 13]. Meanwhile, we also found that HQQR can reduce the urinary microalbumin level in patients with OBH [14], suggesting that HQQR may protect against renal injury. However, the mechanism of HQQR against hypertensive renal damage has not been elucidated.

Network pharmacology as an interdisciplinary subject can predict potential gene targets and the molecular mechanism of drugs on diseases by analyzing the multilevel network of “diseases-genes-drug targets” [15]. It drives the modernization and mechanism research of TCM formulas [16]. Herein, we aim to explore the potential targets and pathways of HQQR against the early renal damage induced by OBH using integrating network pharmacology and experimental validation-based strategy.

2. Materials and Methods

2.1. Screening of Active Components and Related Targets. Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) database [17] (http://tcmspw.com/tcmsp.php, Ver.2.3) and Bioinformatics Analysis Tool for Molecular mechANism of Traditional Chinese Medicine (BATMAN-TCM) database [18] (http://bionet.ncpsb.org/batman-tcm/, updated January 2016) were utilized to screen all compounds of HQQR. These compounds that met two requirements of oral bioavailability (OB) of ≥30% and drug likeness (DL) of ≥0.18 were further screened as bioactive components [17]. TCMSP and DrugBank (https://www.drugbank.ca/, version 5.1.5) databases were used to obtain the targets related to the HQQR bioactive components. The UniProt database (http://www.uniprot.org/) was applied to convert the overannotation protein names to standardized gene symbols [19].

2.2. Prediction of Disease Targets. The hypertensive renal damage-related targets were obtained via GeneCards [20] (https://www.genecards.org, version 4.1.4) and OMIM [20] (http://www.omim.org, updated March 25, 2020) databases. The compound targets and disease targets were intersected by the R software to obtain the therapeutic targets of HQQR against hypertensive renal damage.

2.3. Biological Functional Annotation. The therapeutic targets of HQQR were analyzed to explore the biological functional annotation (GO and KEGG) by “BiocManager” R package [21].

2.4. Network Analysis. The therapeutic targets were imported into STRING (https://string-db.org/, version 11.0) database [22] to get the PPI (protein-protein interaction) network using a high confidence score (correlation degree ≥0.900), as the cutoff value. Compound-target network construction was performed by Cytoscape 3.72 (https://Cytoscape.org/). CytoHubba was employed to pick out hub nodes with high degrees of connectivity in the network by investigating the node composition.

2.5. OBH Rats and Drug Administration. 120 male spontaneously hypertensive rats (SHR) and age/sex-matched Wistar–Kyoto rats (WKY) (five-week-old, 150 ± 20 g) were obtained from the Vital River Laboratory Animal Technology Co., Ltd. (animal license number: SCXK (Beijing) 2016–0006). The animal procedures were approved by the Institutional Animal Care and Use Committee at Yueyang Hospital in accordance with the principles outlined in the NIH guidelines for the care and use of laboratory animals (no. 18922).

Valsartan capsule (batch number: H20040217) was manufactured by Novartis Pharmaceutical Factory (Beijing, China).

HQQR, consisted of Salvia miltiorrhiza, stone cassia, Ligusticum chuanxiong, Uncaria angustifolia, corn whisker, mulberry parasite, and hawthorn (5:1:1:3:10:5:5:5), was decocted and dried following common protocol [12].

2.6. Experimental Procedure. The method of modeling obese rats was referred to early research [23]. The normal diet (no. P1101F) and high-fat diet were purchased from Shanghai Pulueng Biotechnology Co., Ltd. The rats were under a 12/12 h light/dark period cycle at controlled temperature (22 ± CA). The specific workflow followed is shown in Figure 1.

OBH model preparation: with WKY-normal diet and SHR-normal diet as control, SHR high-fat diet was evaluated to prepare OBH models, including 3 groups: WKY-normal diet (WKY-ND), SHR-normal diet (SHR-ND), and SHR high-fat diet (SHR-HF). After feeding a high-fat diet of 10 weeks, SHR-HF with weight in the upper third was selected as obese hypertensive rats (OBH rats).

Drug intervention: the rats were divided into four groups: WKY-normal diet (WKY), OBH high-fat diet (OBH), OBH high-fat diet and 30 mg/kg/d of valsartan by gavage (OBH-V), and OBH high-fat diet and HQQR (38.7 g/kg/d) by gavage (OBH-H).

2.7. Biochemical Detection. Whole blood was drawn from the abdominal aorta and centrifuged to isolate rat plasma samples. Then, mAlb (microalbuminuria), UCr (urine creatinine), NAG
experimental content:

2.9. RNA Extraction and Quantitative Real-Time PCR (qRT-PCR). The renal cortex tissues were used to perform RNA extraction and qRT-PCR as previously described [24]. The relative mRNA level was obtained by calculating $2^{-\Delta\Delta C_{T}}$. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was the inner control for normalization. The primer sequences were presented as follows: 5′-GGTTCGCTGCGGATATGC-3′ and 5′-TATGAAGCTTGTGTCGGC-3′ for SIRT1 (silent information regulator 1); 5′-CAGCCACTGCCCTCCCTAC-3′ and 5′-CAGAATTGGGATTGCAAAC-3′ for IL-6; and 5′-GGAGTCTACTGGCGTCCTCAC-3′ and 5′-ATGAGC CTTCCAGATGC-3′ for GAPDH.

2.10. Western Blotting. The total proteins extracted from renal cortex tissues were separated by SDS-PAGE and transferred to the PVDF membrane. After blocking in 5% nonfat milk for 1 h, protein bands were incubated with primary antibodies, followed by incubation with corresponding second antibodies. Protein bands were visually measured by a chemiluminescent imaging system (Tanon, Shanghai, China). Anti-SIRT1 (Ab110304, 1:1000), anti-NF-κB/p65 (Ab16502, 1:2000), and anti-IL-6 (Ab233706, 1:1000) antibodies were purchased from Abcam. Anti-GAPDH (60004-1-1G, 1:5000) antibody was purchased from Proteintech, and anti-ac-p65 (Bs-23216R, 1:500) antibody was provided by Bioss.

2.11. Data Analysis. All data were plotted using GraphPad Prism 8.0 (San Diego, CA, USA). Data were expressed as mean ± standard error of the mean (SEM). The normality test was performed via the Shapiro–Wilk test. The statistical software SPSS 26.0 (SPSS Ltd., U.S.A.) was used for statistical analysis. Analysis of variance (ANOVA) with Turkey’s posthoc test was used for comparison between the means of multiple groups. A P value ≤0.05 was considered statistically significant.

3. Results

3.1. IL-6 Is Identified as the Key Target of HQQR against Hypertensive Renal Damage. Totally, 4320 targets of hypertensive renal damage were screened using GeneCards and OMIM databases. 167 targets of the ingredients in HQQR were obtained from the TCMSP database. Among these 167 HQQR-related targets, 158 genes were closely related to hypertensive renal damage (Figure 2(a)). Then, 158 therapeutic targets were input to the STING database to get the PPI network. Top 20 hub genes were screened out using CytoHubba in the Cytoscape software. Among these 20 top genes, cytokines (IL-6, IL-10, IL-4, and IL-1β) take a higher proportion, especially IL-6 (Figure 2(b)). Therefore, IL-6 was identified as the key target of HQQR against hypertensive renal damage and further studied in later animal experiments.

Through the TCMSP database, 598 compounds were retrieved from HQQR. Then, we selected OB ≥30% and DL ≥0.18 as the bioactive components to get 118 bioactive herbal compounds. Moreover, we further constructed an interaction network between top 20 hub gene targets (green arrow) and herbal compounds. Through network analysis, 35 core herbal compounds (blue circle) were
obtained, including isocorynantheic acid, quercetin, coryincible, stigmast-7-en-3-ol, mandenol, chryseriol, stigmasterol, luteolin, schottenol, hirsutside C, hirsutine, yohimbine, hirsutside B, corynoxeine, sitosterol, and kaempferol (Figure 2(c)). Interestingly, Salvia miltiorrhiza (Danshen), which is also the principal drug (Junyao or monarch drug) of HQQR, is identified as the main component.

3.2. Evaluation of the Obesity-Related Hypertension Rat Model. 36 (top 1/3) obesity rats were selected as OBH rat models. From Figures 3(a) and 3(b), we can find that the body shape of OBH rats was significantly larger than that of the SHR-normal diet (SHR-ND). Meanwhile, the content of perirenal fat increased evidently. Compared with SHR-ND, the systolic blood pressure (SBP), weight, and waist circumference of the OBH group were significantly increased ($p < 0.001$) (Figures 3(c), 3(d) and 3(e)).

3.3. HQQR Controls Blood Pressure, Weight, and Abdominal Circumference in OBH Rats. Compared with the OBH model group, the weight and abdominal circumference were significantly decreased after 8 weeks ($p < 0.05$). Moreover, the body weight and abdominal circumference in the HQQR group are evidently lower than that of the valsartan group ($p < 0.05$). HQQR could obviously control both SBP and DBP after treatment for 2 weeks ($p < 0.05$). The antihypertensive effect of HQQR equals that of valsartan after 6 weeks of intervention. HQQR can control blood pressure more smoothly than valsartan (Figures 3(f)–3(i)).

3.4. HQQR Protects against Early Renal Damage in OBH Rats. Many studies have investigated the association between renal tubular damage markers (mAlb, UCR, NAG, and Cys-C) and the development and progression of early stage renal damage because of their clinical relevance which are sensitive and specific for predicting renal glomerulopathy [25–27]. Our results show that HQQR can decrease mAlb,
UCR, NAG, and Cys-C, compared with OBH groups ($p < 0.05$ or $p < 0.01$) (Figure 4(a)). In addition, the level of serum IL-6 was markedly reduced after HQQR treatment ($p < 0.01$) (Figure 4(b)).

We further observed the pathological changes of glomeruli by H and E staining. The results exhibit that many inflammatory cells were infiltrated around the glomerulus or accompanied by renal tubular atrophy or disappearance in OBH groups. HQQR reduces the accumulation of inflammatory cells and recover the glomerular normal structure (Figure 4(c)).

The changes of the renal structure may not be obvious in the early stage. Therefore, the ultrastructure of renal cortex tissues was further observed under the transmission electron microscope. We discover podocyte fusion or degeneration, even endothelial cell apoptosis, local thickening of mesangial area, and thinning of mesangial interstitium in OBH groups. However, the abovementioned changes were alleviated in the HQQR group (Figure 4(d)).

3.5. HQQR Improves Metabolic Abnormalities in OBH Rats. Apparently, OBH is always accompanied by metabolic abnormalities. Consequently, the evaluation of metabolic-related indicators is of vital importance. Compared with the OBH group, HQQR reduces the levels of FPG and HOMA-IR ($p < 0.01$ or $p < 0.05$) (Figures 5(a) and 5(b)). Meanwhile, the levels of TC, TG, and LDL-C are also decreased, and HDL-C is increased in the HQQR group ($p < 0.05$ or $p < 0.01$) (Figures 5(c)–5(f)). These results suggest that HQQR can
Figure 4: (a) Comparison of mAlb, UCr, NAG, and Cys-C after drug treatment. (b) Comparison of IL-6 in serum after drug treatment. (c) Comparison of renal tissue H&E staining after drug treatment (400× magnification). (d) Comparison of renal tissue ultrastructure after drug treatment. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Figure 5: Continued.
regulate the metabolism, which is one of the potential mechanisms of protecting against OBH-induced early renal damage.

3.6. HQQR Upregulated SIRT1 Expression in the Renal Tissue of OBH Rats. SIRT1 can deacetylate histones and nonhistone proteins to regulate the cell metabolism throughout the body. Our results demonstrated that both mRNA and protein levels of SIRT1 are evidently decreased in the OBH group, compared with the WKY group. HQQR treatment completely prevents the downregulation of SIRT1 mRNA and protein expression ($p < 0.001$) (Figures 6(a), 6(b) and 6(c)).

3.7. HQQR Reduced NF-κB Acetylation (Ac-NF-κB) and Suppressed the p65-Mediated Inflammatory Signaling Pathway in the Renal Tissue of OBH Rats. NF-κB signaling plays a major role in innate immunity defense; meanwhile, NF-κB
p65 is a substrate of SIRT1. Compared with WKY groups, the acetylation of p65 markedly increased in the renal tissue of OBH rats, and this upregulation was suppressed by HQQR ($p < 0.05$) (Figures 6(a)–6(c) and 6(d)). Concurrently, HQQR completely suppressed OBH-induced p65 nuclear translocation in the renal tissue. As a result, HQQR robustly inhibited OBH-induced neuroinflammation by reducing IL-6 mRNA and protein levels ($p < 0.05$ or $p < 0.01$) (Figures 6(a)–6(f)).

4. Discussion

In the present work, we proposed an integrated strategy via network analysis and experimental validation to illustrate the mechanisms of HQQR against early renal damage induced by OBH systematically. First, previous works of our team have demonstrated that HQQR regulated mitochondrial function and protected hypertensive myocardial hypertrophy through upregulating the expression of SIRT1. Second, via network pharmacology, IL-6 is identified as a key target of HQQR against hypertensive kidney damage; in addition, inflammation is one of the hub pathological processes. Third, recent studies have indicated that the interrelation of inflammation and energy metabolism leads to target organ damage of obesity and hypertension. Consequently, SIRT1/NF-κB/IL-6, which represents the classic target organ damage of obesity and hypertension. Consequently, the increased levels of IL-6 both in the kidney and serum of OBH rats were reversed by HQQR, as well as acetylated NF-κB and consistent with the restoration of SIRT1 gene and protein expression in the kidney. Therefore, the in-depth study of immunity and inflammation will provide potential intervention targets for the prevention and treatment of TOD in hypertension.

Recent research suggests that IL-6 secretion caused by anxiety and stress, which can lead to the changes in the fatty inflammation microenvironment, is a main mechanism of obesity. IL-6 is secreted in brown adipocytes, causing brown adipocytes to fail to regulate the metabolism of glucose and to decompose fat, which ultimately leads to obesity [39]. Studies have reported that chemokines (such as TNF-α and IL-6) are involved in the formation of hypertension [40]. Compared with normal people, the levels of serum IL-1β and IL-18 are higher in patients with hypertension [41]. The application of anti-inflammatory therapy in hypertension is increasing. A new anti-inflammatory drug VA694 can slow down the development of hypertension [42]. Combined with our study, we find that many inflammatory cells infiltrate around the glomerulus of OBH rats, and HQQR treatments reduce inflammation. The above results provide strong theoretical support for our study, in which IL-6 was a core target of OBH renal damage identified by network pharmacology. Confidently, the studies of hypertension and its TOD from the perspective of inflammation will be more and more extensive and profound in the future works.

5. Conclusion

In the present work, integrating network pharmacology and experimental validation-based strategy were used to explore the potential mechanism of HQQR against OBH renal damage. HQQR can increase the expression of SIRT1 consistent with reduction of the NF-κB acetylation expression level. Furthermore, HQQR reduces the mRNA and protein expression level of IL-6 in tissue and release of IL-6 in serum. These findings indicate that upregulating or activating SIRT1 and then reducing inflammation may be a promising therapeutic strategy for OBH-induced renal damage, and clinical trials of HQQR renal protective activity are warranted.
Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

All authors have made significant contributions to this work and approved the submission of this manuscript for publication. Mingzhu Wang and Jianhua Li contributed equally to this work.

Acknowledgments

The authors would like to express their gratitude to all the researchers who participated in the study. This study was supported by the National Natural Science Foundation of China (82174130), the key specialty cultivation project of Shanghai University of Traditional Chinese Medicine (2021LK097 and 2019LK022).

References

[1] "Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019[1]," Lancet, vol. 396, no. 10258, pp. 1223–1249, 2020.

[2] M. E. Hall, J. B. Cohen, J. D. Ard et al., "Weight-loss strategies for prevention and treatment of hypertension: a scientific statement from the American heart association," Hypertension, vol. 78, no. 5, pp. e38–e50, 2021.

[3] J. E. Hall, J. M. Do Carmo, A. A. Da Silva, Z. Wang, and M. E. Hall, "Obesity-induced hypertension," Circulation Research, vol. 116, no. 6, pp. 991–1006, 2015.

[4] M. S. Kim, W. J. Kim, A. V. Khera et al., "Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies," European Heart Journal, vol. 42, no. 34, pp. 3388–3403, 2021.

[5] D. Rigo and M. Orias, "Hypertension and kidney disease progression," Clinical Nephrology, vol. 93, no. 1, pp. 103–107, 2020.

[6] A. J. Mouton, X. Li, M. E. Hall, and J. E. Hall, "Obesity, hypertension, and cardiac dysfunction," Circulation Research, vol. 126, no. 6, pp. 789–806, 2020.

[7] M. Blüher, "Obesity: global epidemiology and pathogenesis," Nature Reviews Endocrinology, vol. 15, no. 5, pp. 288–298, 2019.

[8] K. Lim, K. L. Jackson, Y. Sata, and G. A. Head, "Factors responsible for obesity-related hypertension," Current Hypertension Reports, vol. 19, no. 7, p. 53, 2017.

[9] O. A. Sharif and T. J. Mckenzie, "Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery," Gland Surgery, vol. 9, no. 1, pp. 80–93, 2020.

[10] M. Yang and L. Lao, "Emerging applications of metabolomics in traditional Chinese medicine treating hypertension: biomarkers, pathways and more," Frontiers in Pharmacology, vol. 10, no. 158, 2019.

[11] S. Yu, W. Gao, P. Zeng et al., "Exploring the effect of Gupi Xiaoji Prescription on hepatitis B virus-related liver cancer through network pharmacology and in vitro experiments," Biomedicine & Pharmacotherapy, vol. 139, Article ID 111612, 2021.

[12] W. Jing, D. Zhen-Hua, and G. Ming-Taie, "HuoXue QianYang QuTan Recipe attenuates left ventricular hypertrophy in obese hypertensive rats by improving mitochondrial function through SIRT3/PGC-1α deacetylation pathway[1]," Bioscience Reports, vol. 39, no. 12, 2019.

[13] X. Zhou, B. Lu, D. Fu, M. Gui, L. Yao, and J Li, "HuoXue Qianyang decoction ameliorates cardiac remodeling in obese spontaneously hypertensive rats in association with ATF6-CHOP endoplasmic reticulum stress signaling pathway regulation," Biomedicine & Pharmacotherapy, vol. 121, Article ID 109518, 2020.

[14] Y. Han, D. Fu, and B. Lu, "Effect of Huoxue Qianyang Qutan Recipe on obesity related hypertension patients with abnormal urinary MA/Cr[1]," Hunan Journal of traditional Chinese medicine, vol. 34, no. 09, pp. 10–12, 2018.

[15] L. Zhang, Y. Zhang, M. Zhu et al., "An integrative pharmacology-based strategy to uncover the mechanism of xiong-pifiang in treating coronary heart disease with depression," Frontiers in Pharmacology, vol. 12, Article ID 950602, 2021.

[16] R. Zhang, X. Zhu, H. Bai, and K Ning, "Network pharmacology databases for traditional Chinese medicine: review and assessment," Frontiers in Pharmacology, vol. 10, no. 123, 2019.

[17] J. Ru, P. Li, J. Wang et al., "TCMSP: a database of systems pharmacology for drug discovery from herbal medicines," Journal of Cheminformatics, vol. 6, no. 1, p. 13, 2014.

[18] Z. Liu, F. Guo, Y. Wang et al., "BATMAN-TCM: a bioinformatics analysis tool for molecular mechanism elucidation of traditional Chinese medicine," Scientific Reports, vol. 6, no. 1, Article ID 21146, 2016.

[19] L. Breuza, S. Poux, and A. Estreicher, "The UniProtKB guide to the human proteome[1]," Database: The Journal of Biological Databases and Curation, vol. 20, p. 2016, 2016.

[20] G. Stelzer, N. Rosen, I. Plaschkes et al., "The GeneCardssuite: from gene data mining to disease genomesequence analyses," Current protocols in bioinformatics, vol. 54, p. 1, 2016.

[21] S. Cattley and J. W. Arthur, "BioManager: the use of a bioinformatics web application as a teaching tool in undergraduate bioinformatics training," Briefings in Bioinformatics, vol. 8, no. 6, pp. 457–465, 2007.

[22] D. Szklarczyk, A. L. Gable, D. Lyon et al., "STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets," Nuclic Acids Research, vol. 47, no. D1, pp. D607–D613, 2019.

[23] Z. Liu, F. Guo, Y. Wang et al., "BATMAN-TCM: a bioinformatics analysis tool for molecular mechanism elucidation of traditional Chinese medicine," Scientific Reports, vol. 6, no. 1, Article ID 950602, 2019.

[24] M. Arya, I. S. Shergill, M. Williamson, L. Gommersall, N. Arya, and H. R. Patel, "Basic principles of real-time quantitative PCR," Expert Rev Mol Diagn, vol. 5, no. 2, pp. 209–219, 2005.

[25] Y. Liu, Y. H. Liu, W. J. Bei et al., "A dual-label time-resolved fluorescence immunoassay for the simultaneous determination of cystatin C and β2-microglobulin in urine," British Journal of Biomedical Science, vol. 74, no. 4, pp. 193–197, 2017.

[26] J. Surendar, S. Anuradha, B. Ashley et al., "Cystatin C and cystatin glomerular filtration rate as markers of early renal disease in asian Indian subjects with glucose intolerance (CURES-32)," Metabolic Syndrome and Related Disorders, vol. 7, no. 5, pp. 419–425, 2009.
[27] S. R. Kim, Y. H. Lee, S. G. Lee, E. S. Kang, B. S. Cha, and B. W. Lee, "The renal tubular damage marker urinary N-acetyl-β-d-glucosaminidase may be more closely associated with early detection of atherosclerosis than the glomerular damage marker albuminuria in patients with type 2 diabetes," Cardiovascular Diabetology, vol. 16, no. 1, p. 16, 2017.

[28] A. Rao, V. Pandya, and A. Whaley-Connell, "Obesity and insulin resistance in resistant hypertension: implications for the kidney," Advances in Chronic Kidney Disease, vol. 22, no. 3, pp. 211–217, 2015.

[29] S. G. Chrysant, "Pathophysiology and treatment of obesity-related hypertension," Journal of Clinical Hypertension, vol. 21, no. 5, pp. 555–559, 2019.

[30] A. A. Da Silva, J. M. Do Carmo, X. Li, Z. Wang, A. J. Mouton, and J. E. Hall, "Role of hyperinsulinemia and insulin resistance in hypertension: metabolic syndrome revisited," Canadian Journal of Cardiology, vol. 36, no. 5, pp. 671–682, 2020.

[31] N. Treviño-Saldaña and G. García-Rivas, "Regulation of Sirtuin-Mediated Protein Deacetylation by Cardioprotective Phytochemicals," Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 1750306, 2017.

[32] M. A. D. Silva, J. Martinez-Rodriguez, M. Gonzalez-Lucán, C. Fernandez-Fernandez, and E. Castro-Quintela, "Insulin resistance is a cardiovascular risk factor in humans," Diabetes & Metabolic Syndrome, vol. 13, no. 2, pp. 1449–1455, 2019.

[33] A. E. Kane and D. A. Sinclair, "Sirtuins and NAD+ in the development and treatment of metabolic and cardiovascular diseases," Circulation Research, vol. 123, no. 7, pp. 868–885, 2018.

[34] S. Winnik, J. Auwerx, D. A. Sinclair, and C. M. Matter, "Protective effects of sirtuins in cardiovascular diseases: from bench to bedside," European Heart Journal, vol. 36, no. 48, pp. 3404–3412, 2015.

[35] S. K. Soni, P. Basu, M. Singaravel et al., "Sirtuins and the circadian clock interplay in cardioprotection: focus on sirtuin 1," Cellular and Molecular Life Sciences, vol. 78, no. 6, pp. 2503–2515, 2021.

[36] N. J. Prado, L. Ferder, W. Manucha, and E. R. Diez, "Anti-inflammatory effects of melatonin in obesity and hypertension," Current Hypertension Reports, vol. 20, no. 5, p. 45, 2018.

[37] H. Qing, R. Desrouleaux, K. Israni-Winger et al., "Origin and function of stress-induced IL-6 in murine models," Cell, vol. 182, no. 6, p. 1660, 2020.